A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Study Summary

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.

Conditions

COVID-19 Infection

Interventions / Drugs

ibuzatrelvir remdesivir placebo for ibuzatrelvir placebo for remdesivir

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment300 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.190398+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.